Dr. Wiebke Winkler and Dr. Gustavo Schmidt Moreira present Tacalyx data at ENA 2024 in Barcelona, October 23–25.
Tacalyx presents two posters at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, October 23–25, 2024. The posters are presented by Dr. Wiebke Winkler and Dr. Gustavo Schmidt Moreira.
Press releases
€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.
Scientific presentations
Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).
Company
Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.